Global bleeding Disorder Therapeutics Market: Overview
Bleeding disorders usually include symptoms in which delay in the
blood clotting process can be observed. Two main types of blood
disorders include von Willebrand disease and hemophilia, both of
which are hereditary in nature. Von Willbrand is one of the most
common congenital bleeding disorders in humans, caused as a result of
deficiency of Von Willebrand factor (VWF) which assists in clot
clotting process. There are three types of Von Willebrand disorders
classified on the basis of level of VWF synthesis. Von Willebrand
disorder’s occurrence is almost equal in both sexes, and affects
about 1% of the general population according to the Centers for
Disease Control and Prevention (CDC).
Request Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12218
The most common complications of the disorder include heavy menstrual
bleeding, excessive gum bleeding and abnormal bleeding after minor
injuries. Hemophilia, on the other hand, is a disorder in which
clotting factors essential for clotting phenomenon are inadequate or
absent. In the U.S. about 400 newborns suffer from hemophilia every
year according to statistics published by the CDC. The two main types
of hemophilia are hemophilia A with deficiency of clotting factor
VIII and hemophilia B with deficiency of clotting factor IX. The
National Heart, Lung and Blood Institute, U.S. details that
approximately 7 out of 10 individuals who suffer from hemophilia A
have severe form of the disorder.
Global bleeding Disorder Therapeutics Market: Drivers and
Restraints
Although bleeding disorders cannot be cured, various medications are
directed to manage the symptoms of the disorder. Medications may be
prescribed before or after surgery, dental work or after an injury to
patients suffering from mild form of the disorder. Severe form of the
disorder can be controlled with daily medicines prescribed by the
doctor. The market for bleeding disorder therapeutics is driven by
the large customer base, increased awareness about the bleeding
disorders and available cures, and favorable reimbursement policies.
The market will be seeded with new drugs emerging from a promising
pipeline.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=12218
Moreover, patent expiry of existing brands will also provide generic
drug manufacturers opportunities to enter the lucrative bleeding
disorder therapeutics market. Due to the high price of branded drugs,
the market for bleeding disorder therapeutics is mostly concentrated
towards western countries of North America and Europe. Low cost drugs
will help in better market penetration in under developed and
developing economies where patients cannot afford high cost of
medical treatment. Hence availability of low cost generic drugs will
boost market growth in the countries of Asia-Pacific, Latin America,
Middle East and Africa.
Global bleeding Disorder Therapeutics Market: Competitive
Dynamics
A few drugs that have lost their patent protection include NovoSeven
by Novo Nordisk, whose patent expired in Japan and in the U.S., in
2009 and November 2010, respectively, while the European patent
expired on a country-by-country basis in 2011, Plavix by
Bristol-Myers Squibb, Lovenox by Sanofi, Neupogen by Amgen, and
Procrit by Janssen. These drugs are now available in the market in
generic cost effective form. Companies are also trying to discover
gene therapy which can cure the disorder. Some of the players
conducting lineal trials are Biogen Idec, Novo Nordisk, Bayer
Healthcare, Xenetic Biosciences, Cangene Corporation, CSL Behring,
Alnylam and Pfizer.
The global bleeding disorder therapeutics market is highly
competitive and fragmented. Technological advances will expand the
boundaries of the market by adding new products. In 2014, Baxter
International, Inc. agreed to acquire Chatham Therapeutics. The
acquisition will give Baxter Chatham's developmental gene therapy
program which is directed toward of treatment of hemophilia.
Request for the TOC of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=12218
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment